Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.